After 15 Years of Failure, What Can Pharma Offer Alzheimer’s Patients?

The most recent new treatment for Alzheimer’s disease was approved by European regulators in May 2002, with the US FDA following suit the next year.

from The Pharma Letter

As patients, physicians and pharma firms digest the latest research, presented at last week’s Alzheimer’s Association International Conference (AAIC), what can the pharmaceutical industry offer the estimated 50 million people living with this most burdensome of conditions?

Read More →

Disclaimer: The viewpoint expressed in this article is the opinion of the author and is not necessarily the viewpoint of the owners or employees at Healthcare Staffing Innovations, LLC.